MCID: ACR007
MIFTS: 66

Acromegaly malady

Categories: Rare diseases, Reproductive diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Acromegaly

About this section
Sources:
10Disease Ontology, 11diseasecard, 45NIH Rare Diseases, 47Novoseek, 12DISEASES, 51Orphanet, 36MeSH, 65UMLS, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Acromegaly:

Name: Acromegaly 10 11 45 47 12 51 36 65
Growth Hormone-Secreting Pituitary Adenoma 65
Growth Hormone Excess 45
 
Somatotroph Adenoma 45
Pituitary Giant 45

Characteristics:

Orphanet epidemiological data:

51
acromegaly:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (Worldwide),1-9/100000 (Worldwide),1-9/100000 (Spain),1-9/100000 (Italy),1-9/100000 (United Kingdom),1-9/1000000 (Belgium),1-9/100000 (Belgium),1-5/10000 (Germany),1-9/100000 (Croatia),1-9/1000000 (Ireland),1-9/100000 (Ireland),1-9/1000000 (Finland),1-9/1000000 (Korea, Republic of),1-9/100000 (Korea, Republic of); Age of onset: Adult

Classifications:



External Ids:

Disease Ontology10 DOID:2449
MeSH36 D000172
NCIt42 C84533
Orphanet51 963
ICD10 via Orphanet28 E22.0
MESH via Orphanet37 D000172
UMLS via Orphanet66 C0001206
UMLS65 C0001206

Summaries for Acromegaly

About this section
NIH Rare Diseases:45 Acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (gh). it is most often diagnosed in middle-aged adults, although symptoms can appear at any age. signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. the condition is usually caused by benign tumors on the pituitary called adenomas. rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain. acromegaly is usually treatable but when left untreated, it can result in serious illness and premature death. when gh-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly. last updated: 4/29/2011

MalaCards based summary: Acromegaly, also known as growth hormone-secreting pituitary adenoma, is related to headache and acidophil adenoma, and has symptoms including tall stature, abnormality of the tongue and thick lower lip vermilion. An important gene associated with Acromegaly is GNAS (GNAS Complex Locus), and among its related pathways are Ovarian steroidogenesis and Endochondral Ossification. The drugs bromocriptine and octreotide have been mentioned in the context of this disorder. Affiliated tissues include limb, pituitary and bone, and related mouse phenotypes are adipose tissue and liver/biliary system.

Disease Ontology:10 A disease of metabolism that has material basis in excessive growth hormone production which results in enlargement located in limb.

Wikipedia:68 Acromegaly (/ˌækrəˈmɛɡəli, -roʊ-/; from Greek ἄκρον akron \"extremity\" and μέγα mega... more...

Related Diseases for Acromegaly

About this section

Diseases related to Acromegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 280)
idRelated DiseaseScoreTop Affiliating Genes
1headache30.3INS, PRL
2acidophil adenoma30.2POMC, SST
3pituitary adenoma29.7GH1, GHRH, GNRH1, POMC, PRL, TRH
4hypogonadism29.7GNRH1, POMC, PRL
5hyperglycemia29.6GHRL, IGF1, INS, POMC, SST
6pituitary adenoma, prolactin-secreting28.1AIP, GHRH, GHRHR, GNAS, GPR101, IGF1
7functioning pituitary adenoma27.8AIP, GNRH1, IGF1, POMC, PRL, SST
8craniopharyngioma27.0AIP, GH1, GHRH, GNAS, GPR101, IGF1
9obesity26.7GH1, GHR, GHRH, GHRL, GNAS, IGF1
10x-linked intellectual disability-acromegaly-hyperactivity syndrome11.9
11pituitary adenoma, growth hormone-secreting11.5
12pituitary gigantism11.5
13pituitary adenoma, growth hormone-secreting 211.4
14acyl-coa dehydrogenase, short-chain, deficiency of10.9GHR, IGF1
15free sialic acid storage disorders10.9GH1, GNAS
16mitochondrial genetic disorders10.8GH1, GHRH
17malignant acth producing neoplasm of pituitary gland10.8PRL, SST
18alk-related neuroblastic tumor susceptibility10.8AIP, GNAS
19pancreatic lipomatosis duodenal stenosis10.8INS, SST
20secondary glomerular disease10.8IGF1, IGFBP3, INS
21gigantism10.7
22glomerulosclerosis, focal segmental, 110.7IGF1, IGFBP3, INS
23lipoadenoma10.7IGF1, PRL, SST
24generalized torsion dystonia10.7PRL, TRH
25pseudohypoparathyroidism ic10.7GH1, GNAS, PRL
26graphite pneumoconiosis10.7INS, PRL
27melanoma of soft parts10.6POMC, SST
28growth hormone insensitivity, partial10.6GH1, GHR, IGF1, IGFBP3
29blepharochalasis10.6IGF1, IGFBP3, PRL
30intracerebral cystic meningioma10.6GHRH, IGF1, PRL
31steroid inherited metabolic disorder10.6GNAS, IGFBP3, SST
32adrenal neuroblastoma10.6AIP, GNAS, IGF1, SST
33urinary system disease10.6SST, SSTR2, SSTR5
34glucose-6-phosphate translocase deficiency10.6SST, SSTR2
35leopard syndrome 110.6GHR, IGF1, IGFBP3
36childhood central nervous system immature teratoma10.5IGF1, IGFBP3
37brain angioma10.5IGF1, POMC, SST
38craniodiaphyseal dysplasia10.5GH1, GNAS, PRL, SST
39congenital coronary artery aneurysm10.5GH1, POMC, PRL
40gasserian ganglion meningioma10.5POMC, TRH
41vagus nerve disease10.5IGF1, IGFBP3
42hypothalamic neoplasm10.5POMC, PRL
43mixed ductal-endocrine carcinoma10.5POMC, PRL
44hepatic flexure cancer10.5IGF1, POMC, SST
45gerstmann syndrome10.4POMC, PRL, SST
46sensory system cancer10.4IGF1, POMC, PRL
47adenoma10.4
48cetp-related hyperalphalipoproteinemia10.4GNRH1, IGF1, IGFBP3
49immunodeficiency, common variable, 510.4GHRH, GNAS, PRL, SST
50gigantism advanced bone age hoarse cry10.4AIP, GHRH, GPR101, PRL

Graphical network of the top 20 diseases related to Acromegaly:



Diseases related to acromegaly

Symptoms for Acromegaly

About this section

Symptoms:

 51 (show all 52)
  • broad forehead
  • coarse face
  • broad cheeks/cherub-like/cherubin face
  • prognathism/prognathia
  • broad nose/nasal bridge
  • thick lips
  • macroglossia/tongue protrusion/proeminent/hypertrophic
  • deep palmar creases
  • macrodactyly/fingers hypertrophy/megalodactyly (hand)
  • broad foot
  • abnormal sole/deep creases
  • hyperhidrosis/increased sweating
  • thick skin/pachydermia/orange skin
  • anomalies of the endocrine glands
  • hypothalamic-hypophyseal axis functional anomalies/hypopituitarism
  • articular/joint pain/arthralgia
  • hydrarthrosis/articular/joint effusion
  • osteoarthritis
  • autosomal dominant inheritance
  • tall stature/gigantism/growth acceleration
  • asthenia/fatigue/weakness
  • frontal bossing/prominent forehead
  • enlargment of jaw/large jaw
  • synophris/synophrys
  • puffy eyelids
  • anomalies of teeth and dentition
  • abnormal dentition/dental position/implantation/unerupted/dental ankylosis
  • kyphosis
  • rachidian/spine canal stenosis
  • hirsutism/hypertrichosis/increased body hair
  • dysplastic/thick/grooved fingernails
  • dysplastic/thick/grooved toenails
  • apnea/sleep apnea
  • abnormal cry/voice/phonation disorder/nasal speech
  • chronic arterial hypertension
  • metrorrhagia/menorrhagia/hemorrhagic cycles/hyper/poly/spanio/dysmenorrhea
  • diabetes mellitus
  • facial pain/cephalalgia/migraine
  • acute palsy
  • paresthesia/dysesthesia/hypoesthesia/anesthesia/numbness
  • humour troubles/anxiety/depression/apathy/euphoria/irritability
  • pituitary/hypophyseal neoplasm/tumor/carcinoma/cancer
  • acne/acnea
  • diffuse/generalised skin hyperpigmentation/melanoderma
  • acanthosis nigricans
  • mitral valve prolapse/incompetence/insufficiency/regurgitation/ring anomaly
  • cardiomyopathy/hypertrophic/dilated
  • pollakiuria/polyuria/dysuria/anuria/acute urine retention/oliguria
  • functional anomalies of the genital system
  • impotence/painful erection/priapism/erection troubles
  • galactorrhea
  • somnolence/hypersomnia/parasomnia

HPO human phenotypes related to Acromegaly:

(show all 45)
id Description Frequency HPO Source Accession
1 tall stature hallmark (90%) HP:0000098
2 abnormality of the tongue hallmark (90%) HP:0000157
3 thick lower lip vermilion hallmark (90%) HP:0000179
4 coarse facial features hallmark (90%) HP:0000280
5 full cheeks hallmark (90%) HP:0000293
6 mandibular prognathia hallmark (90%) HP:0000303
7 broad forehead hallmark (90%) HP:0000337
8 abnormality of the nose hallmark (90%) HP:0000366
9 anterior hypopituitarism hallmark (90%) HP:0000830
10 hyperhidrosis hallmark (90%) HP:0000975
11 joint swelling hallmark (90%) HP:0001386
12 broad foot hallmark (90%) HP:0001769
13 deep plantar creases hallmark (90%) HP:0001869
14 osteoarthritis hallmark (90%) HP:0002758
15 arthralgia hallmark (90%) HP:0002829
16 deep palmar crease hallmark (90%) HP:0006191
17 macrodactyly of finger hallmark (90%) HP:0100746
18 abnormality of the menstrual cycle typical (50%) HP:0000140
19 abnormality of the teeth typical (50%) HP:0000164
20 synophrys typical (50%) HP:0000664
21 behavioral abnormality typical (50%) HP:0000708
22 diabetes mellitus typical (50%) HP:0000819
23 hypertension typical (50%) HP:0000822
24 abnormality of the fingernails typical (50%) HP:0001231
25 abnormality of the voice typical (50%) HP:0001608
26 frontal bossing typical (50%) HP:0002007
27 migraine typical (50%) HP:0002076
28 apnea typical (50%) HP:0002104
29 kyphosis typical (50%) HP:0002808
30 paresthesia typical (50%) HP:0003401
31 spinal canal stenosis typical (50%) HP:0003416
32 abnormality of the toenails typical (50%) HP:0008388
33 cerebral palsy typical (50%) HP:0100021
34 palpebral edema typical (50%) HP:0100540
35 neoplasm of the endocrine system typical (50%) HP:0100568
36 abnormality of reproductive system physiology occasional (7.5%) HP:0000080
37 acanthosis nigricans occasional (7.5%) HP:0000956
38 acne occasional (7.5%) HP:0001061
39 abnormality of the mitral valve occasional (7.5%) HP:0001633
40 hypertrophic cardiomyopathy occasional (7.5%) HP:0001639
41 reduced consciousness/confusion occasional (7.5%) HP:0004372
42 generalized hyperpigmentation occasional (7.5%) HP:0007440
43 abnormal renal physiology occasional (7.5%) HP:0012211
44 erectile abnormalities occasional (7.5%) HP:0100639
45 galactorrhea occasional (7.5%) HP:0100829

UMLS symptoms related to Acromegaly:


pseudothrombophlebitis, musculoskeletal stiffness, extremity contracture, trendelenburg's symptom, chest wall necrosis, musculoskeletal and connective tissue signs and symptoms nec, mass of lower limb, mass of upper limb, cushingoid facies

Drugs & Therapeutics for Acromegaly

About this section

Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 66)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CabergolineapprovedPhase 4, Phase 34581409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
2
Octreotideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 119883150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
 
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Ocphyl
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatin
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
3
DopamineapprovedPhase 4, Phase 3, Phase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
4
MetforminapprovedPhase 41645657-24-9, 1115-70-414219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMBG
DMGG
Diabefagos
Diabetosan
Diabex
Diaformin
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Meguan
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin Hydrochloride
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
Obimet
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
5
LiraglutideapprovedPhase 4278204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
 
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
Saxenda
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
6
ZincapprovedPhase 414777440-66-623994, 32051
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
7insulinPhase 4, Phase 3, Phase 24278
8Protective AgentsPhase 4, Phase 25651
9Insulin, Globin ZincPhase 4, Phase 3, Phase 24278
10Peripheral Nervous System AgentsPhase 4, Phase 218510
11Liver ExtractsPhase 43572
12lanreotidePhase 4, Phase 3, Phase 2, Phase 174
13MitogensPhase 4, Phase 3, Phase 21386
14Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 14256
15
LactitolPhase 4, Phase 3, Phase 1320585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
16AngiopeptinPhase 4, Phase 3, Phase 2, Phase 174
17Antiparkinson AgentsPhase 4, Phase 31312
18Dopamine AgonistsPhase 4, Phase 3544
19Dopamine AgentsPhase 4, Phase 3, Phase 23084
20HormonesPhase 4, Phase 3, Phase 211748
21Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 16401
22Neurotransmitter AgentsPhase 4, Phase 3, Phase 214795
23
SomatostatinPhase 4, Phase 3, Phase 2, Phase 115351110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
24Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 29988
25Hormone AntagonistsPhase 4, Phase 3, Phase 210002
26Complement Factor IPhase 4, Phase 336
27Sitagliptin PhosphatePhase 4399
28Hypoglycemic AgentsPhase 44503
29Pharmaceutical SolutionsPhase 47004
30Dipeptidyl-Peptidase IV InhibitorsPhase 4779
31HIV Protease InhibitorsPhase 44558
32IncretinsPhase 41326
33Protease InhibitorsPhase 44558
34
Mannitolapproved, investigationalPhase 324269-65-8453, 6251
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
AR-1J3861
Ambap69-65-8
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-Mannitol
D-Mannitol (JP15)
D-mannite
D-mannitol
D00062
D008353
DL-Mannitol
Diosmol
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
HSDB 714
Hexahydroxyhexane
Hexanhexol
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
M9546_SIAL
M9647_SIAL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
 
MANNITOL 25%
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
MLS001335977
MLS001335978
MTL
Manicol
Manitol
Maniton S
Maniton-S
Manna Sugar
Manna sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol 10%
Mannitol 10% In Plastic Container
Mannitol 15%
Mannitol 15% In Plastic Container
Mannitol 20%
Mannitol 20% In Plastic Container
Mannitol 5%
Mannitol 5% In Plastic Container
Mannitol [USAN]
Mannitolum
Mannogem 2080
Marine Crystal
Marine crystal
MolPort-003-927-039
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
Osmitrol 15% In Water
Osmitrol 20% In Water
Osmitrol 5% In Water
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Sorbitol-Mannitol
TL806434
UNII-3OWL53L36A
ZINC02041302
bmse000099
cpd without stereochemical designation
e 421
e-421
e421
manita
mannitol
35Carboxymethylcellulose SodiumPhase 3105
36RadiopharmaceuticalsPhase 3362
37EdotreotidePhase 320
38
DimenhydrinateapprovedPhase 239523-87-5441281
Synonyms:
(O-Benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide
2-benzhydryloxyethyl(dimethyl)azanium
8-chloro-1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
8-chloro-1,3-dimethyl-2-oxopurin-6-olate
8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
AC1L9AVV
Airmit Ace
Benzhydryl-beta-dimethylaminoethylether 8-chlorotheophylline
CAS-523-87-5
CHEBI:4604
CID441281
Colace
D00520
DB00985
Dimenhidrinato
Dimenhydrinate
Dimenhydrinate (JP15/USP/INN)
Dimenhydrinatum
Diphenhydramine 8-chlorotheophyllinate
Diphenhydramine 8-chlorotheophylline
Diphenhydramine theoclate
Diphenhydrinate
 
Dosolax
Dramamine (TN)
Dramamine For Kids
Dramamine Orange
Dramamine Original Formula
Driminate
HMS1568F12
Motion Sickness
Motion Sickness Original Formula
Motion Sickness Original formula
Motion Sickness Relief
Motion Sickness Relief Original Formula
N,N-Dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
NCGC00017026-01
Novamine
O-Benzhydryldimethylaminoethanol 8-chlorotheophyllinate
Original Formula Motion Sickness Relief
Pac-kit Motion Sickness
Physicianscare Dimenhydrinate Motion Sickness Relief
Prestwick_892
Soflax
Travel Ease
Travel Sickness
Wal-dram
beta-Dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
39
Tadalafilapproved, investigationalPhase 2140171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
40Estrogen Receptor ModulatorsPhase 2544
41EstrogensPhase 22144
42Selective Estrogen Receptor ModulatorsPhase 2501
43Estrogen AntagonistsPhase 21155
44ZuclomiphenePhase 2158
45EnclomiphenePhase 2158
46AnticoagulantsPhase 21760
47Chelating AgentsPhase 2667
48Calcium, DietaryPhase 24678
49ClomiphenePhase 2158
50Ethinyl estradiol, levonorgestrel drug combinationPhase 267

Interventional clinical trials:

(show top 50)    (show all 138)
idNameStatusNCT IDPhase
1Preoperative Octreotide Treatment of AcromegalyCompletedNCT00521300Phase 4
2Acute Application of Pegvisomant and Octreotide in AcromegalyCompletedNCT00595140Phase 4
3Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant AcromegalyCompletedNCT00461149Phase 4
4Efficacy of Octreotide Acetate and Cabergoline in Patients With AcromegalyCompletedNCT00376064Phase 4
5Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LARCompletedNCT00216398Phase 4
6Lanreotide Autogel-120 mg as First-Line Treatment of AcromegalyCompletedNCT00627796Phase 4
7Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic PatientsCompletedNCT01014793Phase 4
8Somatuline Autogel: Acromegaly Self/Partner Injection StudyCompletedNCT00149188Phase 4
9Canadian Pegvisomant Compassionate Study In Acromegalic PatientsCompletedNCT00151437Phase 4
10Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic PatientsCompletedNCT01278342Phase 4
11A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With AcromegalyCompletedNCT00068042Phase 4
12A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or OctreotideCompletedNCT00234520Phase 4
13Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic SubjectsCompletedNCT00701363Phase 4
14Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient SatisfactionCompletedNCT00145405Phase 4
15Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic PatientsCompletedNCT00642720Phase 4
16A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.CompletedNCT01861717Phase 4
17Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following SurgeryCompletedNCT00500227Phase 4
18Non Interventional Study For Patients Treated With Somavert®CompletedNCT00858143Phase 4
19Pegvisomant And Sandostatin LAR Combination StudyCompletedNCT00068029Phase 4
20Surgical Debulking of Pituitary AdenomasCompletedNCT01371643Phase 4
21Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist PegvisomantRecruitingNCT00552851Phase 4
22Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From AcromegalyRecruitingNCT02115906Phase 4
23Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin AnaloguesRecruitingNCT02427295Phase 4
24Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyRecruitingNCT02060383Phase 4
25Pasireotide LAR and Pegvisomant Study in AcromegalyRecruitingNCT02668172Phase 4
26Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)RecruitingNCT00915954Phase 4
27Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
28Treatment of the Dumping Syndrome With Lanreotide Autogel®RecruitingNCT00543179Phase 4
29Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical TargetActive, not recruitingNCT01618513Phase 4
30Effects of Sandostatin LAR® in AcromegalyActive, not recruitingNCT01424241Phase 4
31Octreotide Efficacy and Safety in First-line Acromegalic PatientsSuspendedNCT00171886Phase 4
32Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or MacroadenomasTerminatedNCT00242541Phase 4
33Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for AcromegalyCompletedNCT01412424Phase 3
34Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With AcromegalyCompletedNCT00225979Phase 3
35Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled AcromegalyCompletedNCT00372697Phase 3
36Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic PatientsCompletedNCT00128232Phase 3
37Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelCompletedNCT00447499Phase 3
38Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaCompletedNCT00690898Phase 3
39Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedNCT00383708Phase 3
40Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With AcromegalyCompletedNCT00444873Phase 3
41Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With AcromegalyCompletedNCT00499993Phase 3
42Efficacy and Safety of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00616551Phase 3
43Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00635765Phase 3
44Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsCompletedNCT00210457Phase 3
45Long Term Study With B2036-PEGCompletedNCT00143416Phase 3
46Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With AcromegalyCompletedNCT00234572Phase 2, Phase 3
47A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3
48Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin AnaloguesRecruitingNCT02354508Phase 3
49Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in AcromegalyRecruitingNCT02685709Phase 3
50Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyRecruitingNCT02493517Phase 3

Search NIH Clinical Center for Acromegaly

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: acromegaly

Genetic Tests for Acromegaly

About this section

Anatomical Context for Acromegaly

About this section

MalaCards organs/tissues related to Acromegaly:

33
Pituitary, Bone, Heart, Lung, Brain, Liver, Testes

FMA organs/tissues related to Acromegaly:

16
Limb

Animal Models for Acromegaly or affiliated genes

About this section

MGI Mouse Phenotypes related to Acromegaly:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053758.5GHR, GHRHR, GHRL, GNAS, IGF1, IGFBP3
2MP:00053708.2AIP, GHR, GHRH, GNAS, GNRH1, IGFBP1
3MP:00107718.2AIP, GHR, GHRHR, GNAS, GNRH1, IGF1
4MP:00053867.5GHR, GHRHR, GHRL, GNAS, IGFBP3, INS
5MP:00053877.4GHR, GHRH, GHRHR, GNAS, GNRH1, IGF1
6MP:00053797.0AIP, GHR, GHRH, GHRHR, GHRL, GNAS
7MP:00036316.9GHR, GHRH, GHRHR, GNAS, GNRH1, IGF1
8MP:00053786.8AIP, GHR, GHRH, GHRHR, GNAS, GNRH1
9MP:00053765.6AIP, GHR, GHRH, GHRHR, GHRL, GNAS

Publications for Acromegaly

About this section

Articles related to Acromegaly:

(show top 50)    (show all 1436)
idTitleAuthorsYear
1
Reduction of trabecular and cortical volumetric bone mineral density at the proximal femur in patients with acromegaly. (26530355)
2015
2
Tear Osmolarity and Tear Function Changes in Patients with Acromegaly. (25310803)
2014
3
Acromegaly: assessing the disorder and navigating therapeutic options for treatment. (25374336)
2014
4
A consensus on the diagnosis and treatment of acromegaly complications. (22903574)
2013
5
Acromegaly and oxidative stress: impact on endothelial dysfunction and atherosclerosis. (23608960)
2013
6
Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus naA^ve acromegaly. (23593161)
2013
7
Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. (21744088)
2012
8
Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. (22613412)
2012
9
Invasive sphenocavernous aspergilloma complicating an operated case of acromegaly. (23984200)
2011
10
Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. (20813787)
2010
11
N-terminal pro-brain natriuretic peptide in newly diagnosed acromegaly. (20930495)
2010
12
Lanreotide for the treatment of acromegaly. (19533047)
2009
13
The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment. (19109045)
2009
14
Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. (18418712)
2008
15
Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? (18000757)
2008
16
Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. (19016004)
2008
17
Predictors and rates of treatment-resistant tumor growth in acromegaly. (16061822)
2005
18
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. (16076947)
2005
19
Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. (15585549)
2005
20
Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. (16159936)
2005
21
A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. (15827109)
2005
22
GH and mortality in acromegaly. (16625851)
2005
23
Cardiovascular complications in acromegaly. (15282442)
2004
24
Pegvisomant: a new treatment modality for acromegaly. (16982575)
2004
25
Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. (14609359)
2003
26
Experience with pegvisomant in the treatment of acromegaly. (11527081)
2001
27
Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. (11083070)
2000
28
Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. (11788011)
2000
29
The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. (8548933)
1995
30
Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. (7750196)
1995
31
The magnitude of growth hormone elevation is related with the proportion of monomeric form in acromegaly. (8845645)
1995
32
Acute effects of a single administration of dexamethasone on basal and growth hormone-releasing hormone stimulated GH secretion in acromegaly. (8137516)
1994
33
Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values. (8325938)
1993
34
Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly. (7680832)
1993
35
Pituitary adenomas of patients with acromegaly express thyrotropin- releasing hormone receptor messenger RNA: cloning and functional expression of the human thyrotropin-releasing hormone receptor gene. (8396925)
1993
36
Clinical experience of octreotide in the treatment of acromegaly. (1358345)
1992
37
A marked molecular heterogeneity of growth hormone (GH) detected in the plasma but not pituitary of a patient with acromegaly: comparison with other acromegalics and an implication for discrepant plasma levels of GH and insulin-like growth factor. (1506622)
1992
38
Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. (1563080)
1992
39
The relationship between TSH response to TRH and GH response to dopaminergic agents in patients with acromegaly]. (1674920)
1991
40
Resistance to a long-acting somatostatin analog (SMS 201-995) reversed by surgery in acromegaly. (2273211)
1990
41
Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects. (2229278)
1990
42
Somatostatin analog treatment of acromegaly: new aspects. (2900190)
1988
43
44
45
46
47
48
49
50

Variations for Acromegaly

About this section

Clinvar genetic disease variations for Acromegaly:

5
id Gene Variation Type Significance SNP ID Assembly Location
1GNASNM_000516.5(GNAS): c.601C> A (p.Arg201Ser)single nucleotide variantPathogenicrs11554273GRCh37Chr 20, 57484420: 57484420

Cosmic variations for Acromegaly:

7
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM27887GNASpituitary,NS,adenoma,GH10
2COSM27888GNASpituitary,NS,adenoma,GH10
3COSM27895GNASpituitary,NS,adenoma,GH10
4COSM27896GNASpituitary,NS,adenoma,GH10
5COSM27899GNASpituitary,NS,adenoma,GH10
6COSM483HRASpituitary,NS,adenoma,GH10

Expression for genes affiliated with Acromegaly

About this section
Search GEO for disease gene expression data for Acromegaly.

Pathways for genes affiliated with Acromegaly

About this section

Pathways related to Acromegaly according to GeneCards Suite gene sharing:

(show all 14)
idSuper pathwaysScoreTop Affiliating Genes
19.9GNAS, IGF1, INS
29.9GH1, GHR, IGF1
39.8IGF1, IGFBP3, INS
49.8GH1, GHR, PRL
5
Show member pathways
9.8GH1, GHR, PRL
69.7IGF1, IGFBP1, IGFBP3
79.4GH1, GHR, IGF1, INS, PRL
89.3GHRH, GHRHR, GNAS, POMC
9
Show member pathways
9.1GH1, GHRL, IGF1, INS, POMC
10
Show member pathways
9.0GH1, GHRH, GNAS, GNRH1, IGF1, INS
11
Show member pathways
8.8GHRL, GNAS, SSTR1, SSTR2, SSTR5
12
Show member pathways
8.5GH1, GHR, GHRH, GNAS, GNRH1, IGF1
13
Show member pathways
6.3GH1, GHR, GHRH, GHRHR, GHRL, GNAS
14
Show member pathways
5.8GH1, GHR, GHRH, GHRHR, GHRL, GNAS

GO Terms for genes affiliated with Acromegaly

About this section

Cellular components related to Acromegaly according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1secretory granule lumenGO:00347749.9GHRL, INS
2neuron projectionGO:00430059.1SSTR1, SSTR2, SSTR5

Biological processes related to Acromegaly according to GeneCards Suite gene sharing:

(show all 28)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of glycolytic processGO:004582110.7IGF1, INS
2JAK-STAT cascade involved in growth hormone signaling pathwayGO:006039710.7GH1, GHR
3insulin-like growth factor receptor signaling pathwayGO:004800910.7GHR, IGF1
4positive regulation of glycogen biosynthetic processGO:004572510.7IGF1, INS
5regulation of insulin-like growth factor receptor signaling pathwayGO:004356710.6IGFBP1, IGFBP3
6response to foodGO:003209410.5GHR, GHRH
7positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.5GH1, GHR, IGF1
8positive regulation of growth hormone secretionGO:006012410.4GHRH, GHRL
9hormone-mediated signaling pathwayGO:000975510.4GHRL, TRH
10positive regulation of JAK-STAT cascadeGO:004642710.4GH1, GHR, PRL
11positive regulation of hormone secretionGO:004688710.3GHRH, GHRHR
12positive regulation of MAPK cascadeGO:004341010.3IGF1, IGFBP3, INS
13regulation of multicellular organism growthGO:004001410.2GHR, IGF1, PRL
14somatostatin signaling pathwayGO:003817010.2SSTR1, SSTR2
15regulation of insulin secretionGO:005079610.2GNAS, INS, SSTR5
16response to steroid hormoneGO:004854510.2GNRH1, IGF1, SST
17response to glucocorticoidGO:005138410.2GHR, GHRHR, IGF1
18cellular response to insulin stimulusGO:003286910.1GHR, GHRHR, IGF1
19response to starvationGO:004259410.1SSTR1, SSTR2
20positive regulation of peptidyl-tyrosine phosphorylationGO:005073110.0GH1, GHR, IGF1, INS
21growth hormone secretionGO:003025210.0GHRH, GHRHR, GHRL
22positive regulation of multicellular organism growthGO:00400189.8GH1, GHRH, GHRHR, GHRL
23female pregnancyGO:00075659.6GNAS, GNRH1, IGF1, PRL
24positive regulation of cell proliferationGO:00082849.4GHRH, GHRHR, IGF1, INS
25negative regulation of cell proliferationGO:00082859.2IGFBP3, SST, SSTR1, SSTR2, SSTR5
26cellular protein metabolic processGO:00442678.9GHRL, IGF1, IGFBP1, IGFBP3, INS, PRL
27cell-cell signalingGO:00072678.9GHRH, GPR101, INS, SST, SSTR1, SSTR2
28G-protein coupled receptor signaling pathwayGO:00071868.1GHRL, GNAS, INS, SST, SSTR1, SSTR2

Sources for Acromegaly

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet